摘要:
Parenteral vaccine formulations and adjuvant compositions comprising certain salts as adjuvants are disclosed. Such parenteral vaccine formulations are used for generating an immune response in a subject following administration of the vaccine formulation or the adjuvant composition. Also disclosed is the use of these salts as adjuvants in parenteral vaccine formulations and adjuvant compositions, and to vaccine adjuvants comprising such salts.
摘要:
The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.
摘要:
Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE mediated allergy. The present invention relates to a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart and specifically a synthetic gene coding for a direct fusion of Fel d 1 chain 2 N-terminally to chain 1. E coli expression resulted in a non-covalently associated homodimer with an apparent molecular weight of 30 kDa defined by size exclusion chromatography, each 19177 Da subunit displayed a disulfide pattern identical to that found in the natural Fel d 1, and having identical fold of natural and recombinant Fel d 1. The, recombinant Fel d 1 provides for diagnosis and allergen specific immunotherapy of cat allergy.
摘要翻译:来自家猫(Felis homeus)的丹德斯是IgE介导的过敏最常见的原因之一。 本发明涉及具有类似于天然对应物的分子和生物学特性的重组折叠Fel d 1,特别涉及编码Fel d 1链2 N-末端与链1的直接融合的合成基因。大肠杆菌表达导致 通过大小排阻色谱法定义的具有30kDa表观分子量的非共价相关同源二聚体,每个19177Da亚基显示与天然Fel d 1中发现的相同的二硫图案,并具有天然和重组Fel d 1的相同折叠。 重组Fel d 1提供猫过敏的诊断和变应原特异性免疫治疗。
摘要:
A nucleic acid molecule encoding a peptide or protein comprising at least one epitope of the major allergen of Plantago lanceolata, Pla I 1, wherein the nucleic acid molecule a) has the sequence of SEQ ID NOS.: 5-7, b) is a fragment of the sequence SEQ ID NOS.: 5-7, c) has a sequence encoding the amino acid sequence of SEQ ID NO.: 8 or a fragment thereof, d) has a sequence hybridising to SEQ ID NOS.: 5-7 under stringent conditions, e) has a sequence derivable by degeneration of SEQ ID NOS.: 5-7, or f) a complementary strand of any of the sequences a)-e).
摘要翻译:编码肽或蛋白质的核酸分子,其包含Plantago lanceolata,Pla I的主要变应原的至少一个表位,其中所述核酸分子a)具有SEQ ID NO:5-7的序列,b)是 序列SEQ ID NO:5-7的片段,c)具有编码SEQ ID NO:8的氨基酸序列的序列或其片段,d)具有与SEQ ID NO:5-7杂交的序列 在严格条件下,e)具有可由SEQ ID NO:5-7的变性导出的序列,或f)序列a)-e)中任一序列的互补链。
摘要:
The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.
摘要:
The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of a house dust mite allergen, e.g. the allergens Der p 1, Der f 1, Der p 2 and/or Der f 2. Such peptides comprise at least one T cell epitope and a significant high number of patients in a worldwide population will have HLA alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by a dust mite.
摘要:
The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.
摘要:
The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.
摘要:
Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall null-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.
摘要:
The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. grass or tree pollen) by bystander suppression with a plant profilin (e.g. Phl p 12, Bet v 2, or Ole e 2) or a variant thereof. Also the invention features a particular variant of Phl p 12 with two of its cysteine residues replaced with another amino acid to increase its pharmaceutical properties.
摘要翻译:本发明涉及由植物profilin通过旁观者抑制(例如Phl p12,Bet v 2或或其它物质)治疗由含profilin的植物材料(例如草或树花粉)的非profilin变应原引起的超敏反应性免疫应答 Ole e 2)或其变体。 本发明还具有Phlp12的特定变体,其两个半胱氨酸残基被另一个氨基酸取代以增加其药物性质。